Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer

Science(1989)10.1126/science.2470152Source: DataRank Database

Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer is a research paper published in Science (1989). On theSindex it has a DataRank of 1.3. It has been cited 6,845 times.

N/A

1.3DataRank · unranked

Scored on demand from live citation data

6,845 citations

Free full text

Cite:

Linked data & code

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:OA: closedLinked Datasets (25)DataCite Reuse (25)IDs (PubMed)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (0/2)

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 100%Citation Network 0%

Base Score Contribution

1.3

From this paper's citation signal

Citation Network Contribution

Citation network not refreshed for this result

This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.

Learn more about DataRank methodology →

Authors (12)

William Godolphin ORCID,Lovell A. Jones ORCID,John A. Holt,Steven G. Wong,Duane E. Keith

Live enrichment

PubMed:26207759

closed

publisherhttps://www.science.org/doi/pdf/10.1126/science.2470152

Additional file 8 of MZ1 co-operates with trastuzumab in HER2 positive breast cancer

10.6084/m9.figshare.14252038.v1figshare

Additional file 8 of MZ1 co-operates with trastuzumab in HER2 positive breast cancer

10.6084/m9.figshare.14252038figshare

Additional file 11 of Synergy between trastuzumab and pertuzumab for human epidermal growth factor 2 (Her2) from colocalization: an in silicobased mechanism

10.6084/m9.figshare.12874083.v1figshare

Additional file 11 of Synergy between trastuzumab and pertuzumab for human epidermal growth factor 2 (Her2) from colocalization: an in silicobased mechanism

10.6084/m9.figshare.12874083figshare

Additional file 1 of Synergy between trastuzumab and pertuzumab for human epidermal growth factor 2 (Her2) from colocalization: an in silicobased mechanism

10.6084/m9.figshare.12874086.v1figshare

Additional file 1 of Synergy between trastuzumab and pertuzumab for human epidermal growth factor 2 (Her2) from colocalization: an in silicobased mechanism

10.6084/m9.figshare.12874086figshare

Additional file 2 of Synergy between trastuzumab and pertuzumab for human epidermal growth factor 2 (Her2) from colocalization: an in silicobased mechanism

10.6084/m9.figshare.12874089.v1figshare

Additional file 2 of Synergy between trastuzumab and pertuzumab for human epidermal growth factor 2 (Her2) from colocalization: an in silicobased mechanism

10.6084/m9.figshare.12874089figshare

Additional file 3 of Synergy between trastuzumab and pertuzumab for human epidermal growth factor 2 (Her2) from colocalization: an in silicobased mechanism

10.6084/m9.figshare.12874092.v1figshare

Additional file 3 of Synergy between trastuzumab and pertuzumab for human epidermal growth factor 2 (Her2) from colocalization: an in silicobased mechanism

10.6084/m9.figshare.12874092figshare

Additional file 4 of Synergy between trastuzumab and pertuzumab for human epidermal growth factor 2 (Her2) from colocalization: an in silicobased mechanism

10.6084/m9.figshare.12874095.v1figshare

Additional file 4 of Synergy between trastuzumab and pertuzumab for human epidermal growth factor 2 (Her2) from colocalization: an in silicobased mechanism

10.6084/m9.figshare.12874095figshare

Additional file 5 of Synergy between trastuzumab and pertuzumab for human epidermal growth factor 2 (Her2) from colocalization: an in silicobased mechanism

10.6084/m9.figshare.12874098.v1figshare

Additional file 5 of Synergy between trastuzumab and pertuzumab for human epidermal growth factor 2 (Her2) from colocalization: an in silicobased mechanism

10.6084/m9.figshare.12874098figshare

Additional file 6 of Synergy between trastuzumab and pertuzumab for human epidermal growth factor 2 (Her2) from colocalization: an in silicobased mechanism

10.6084/m9.figshare.12874101.v1figshare

Additional file 6 of Synergy between trastuzumab and pertuzumab for human epidermal growth factor 2 (Her2) from colocalization: an in silicobased mechanism

10.6084/m9.figshare.12874101figshare

Additional file 7 of Synergy between trastuzumab and pertuzumab for human epidermal growth factor 2 (Her2) from colocalization: an in silicobased mechanism

10.6084/m9.figshare.12874104.v1figshare

Additional file 7 of Synergy between trastuzumab and pertuzumab for human epidermal growth factor 2 (Her2) from colocalization: an in silicobased mechanism

10.6084/m9.figshare.12874104figshare

Additional file 8 of Synergy between trastuzumab and pertuzumab for human epidermal growth factor 2 (Her2) from colocalization: an in silicobased mechanism

10.6084/m9.figshare.12874107.v1figshare

Additional file 8 of Synergy between trastuzumab and pertuzumab for human epidermal growth factor 2 (Her2) from colocalization: an in silicobased mechanism

10.6084/m9.figshare.12874107figshare